Turnstone Biologics (NASDAQ:TSBX) Releases Earnings Results, Misses Expectations By $0.08 EPS

Turnstone Biologics (NASDAQ:TSBX) issued its earnings results on Wednesday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.08), Zacks reports.

Turnstone Biologics Stock Down 61.9 %

Shares of TSBX stock traded down $1.35 during trading hours on Thursday, reaching $0.83. The company’s stock had a trading volume of 5,716,627 shares, compared to its average volume of 189,268. Turnstone Biologics has a fifty-two week low of $0.80 and a fifty-two week high of $12.16. The company has a market capitalization of $19.20 million and a price-to-earnings ratio of -0.12. The firm’s 50 day simple moving average is $2.52 and its 200-day simple moving average is $2.81.

Turnstone Biologics Company Profile

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas.